This trial is active, not recruiting.

Condition healthy
Treatments okt3, okt3, gc, gc
Phase phase 1
Sponsor Hadassah Medical Organization
Start date January 2008
End date April 2008
Trial size 20 participants
Trial identifier NCT00619372, Protocol No. 01-300, YI002-HMO-CTIL


This clinical study is designed to evaluate the safety of oral administration of the study drug anti CD3 (OKT3) in combination with β-D glucosylceramide [GC] .

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Low dose OKT3 with GC
okt3, gc OKT3, antiCD3
0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Mid dose OKT3
okt3 OKT3, antiCD3
1 mg OKT3, PO (in the mouth) on day 1 through 5
Mid OKT3 dose with GC
okt3, gc OKT3, antiCD3
1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
High dose OKT3
okt3 OKT3, anti-CD3
5 mg OKT3, PO (in the mouth) on day 1 through 5
GC only
gc GC, glucosylceramide, beta glucosylceramide
7.5 mg GC, PO (in the mouth) on day 1 through 5
Low dose OKT3
okt3 OKT3, Monoclonal anti CD3.
0.2 mg OKT3, PO (in the mouth) on day 1 through 5.

Primary Outcomes

Assessment of the safety of oral administration of OKT3 with and without GC in healthy volunteers by monitoring the subjects for adverse events and by interpreting the results of the various laboratory tests and the subjects' diaries.
time frame: January-April

Secondary Outcomes

To evaluate the safety of 5 consecutive doses of oral OKT3 with and with out GC and the dose escalation effect in healthy volunteers.
time frame: January-April

Eligibility Criteria

Male participants from 18 years up to 50 years old.

Inclusion Criteria: - Subjects who have completed the informed consent process culminating with written informed consent by the subject. - Men and women > 18 years of age. Exclusion Criteria: - Subjects who have undergone surgery within the last 3 months. - Subjects who have had a prior colostomy, ileostomy, or colectomy with ileorectal anastamosis. - Subjects presenting with, or who have a history of, persistent intestinal obstruction, bowel perforation, uncontrolled bleeding or abdominal abscess or infection, toxic megacolon. - Subjects with a clinically significant infectious, immune mediated or malignant disease - Subjects who are receiving an elemental diet or parenteral nutrition. - Subjects who have been treated with any time of immune modulatory drug including steroids or NSAID within the last 4 weeks. - Subjects who have received either methotrexate or cyclosporine or anti TNF alpha (infliximab, Remicade), anti-integrin (namixilab) or who have participated in any other clinical trial within the last 3 months. - Subjects with a history of coagulopathy. - Women with childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or Depo -provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers. - Subjects who will be unavailable for the duration of the trial, are likely to be non¬compliant with the protocol, or who are felt to be unsuitable by the investigator for any other reason. - Subjects who are HIV positive - Subjects who are HBsAg positive - Subjects who are HCV positive - Subjects with active CMV - Subjects who demonstrate a positive PPD - Subjects with anemia (Hb <10.5 gm/dl) - Subjects with thrombocytopenia (platelets <100K/microliter) - Subjects with lymphopenia (absolute lymphocyte count <0.7) - Subjects with IgG anti-cardiolipin antibody >16 IU - Prior exposure to OKT3 - Known sensitivity to any ingredients in the study drug

Additional Information

Official title Administration of Anti-CD3 (OKT3) in Combination With Beta-D-Glucosylceramide
Principal investigator Ehud Zigmond, M.D.
Description Anti CD3 (OKT3): Is an approved drug for intravenous use in the treatment of solid organ transplantation. Preliminary data suggest that the oral administration of OKT3 in low dosages can exert an immune modulatory effect via activation of regulatory T lymphocytes. β-D glucosylceramide [GC]: Is approved for oral administration and is currently being tested in three clinical trials. Recent data suggested that it can serve as an immunological adjuvant in various clinical settings and to augment the immune response via activation of regulatory T cells. This clinical trial has been designed to assess the safety of oral administration of OKT3 with and without co-administration of GC in healthy subjects. The use of two potential activators of regulatory T cells, may exert an additive effect, augmenting the systemic immune modulatory effect.
Trial information was received from ClinicalTrials.gov and was last updated in February 2009.
Information provided to ClinicalTrials.gov by Hadassah Medical Organization.